Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Mouse IgG2a; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170491-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $79.90 | |
| Ab170491-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $357.90 | |
| Ab170491-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $837.90 | |
| Ab170491-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,377.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Mouse IgG2a; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Muromonab (anti-CD3) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CD3, >95%, high purity, Mouse IgG2a |
|---|---|
| Synonyms | CD_antigen: CD3e; CD3 antigen, delta subunit; CD3; CD3d antigen; CD3d antigen, delta polypeptide (TiT3 complex); CD3d molecule, delta (CD3-TCR complex); CD3-DELTA; CD3e antigen; CD3e antigen, epsilon polypeptide (TiT3 complex); CD3e molecule, epsilon (CD3 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD3 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description | Muromonab is a monoclonal antibody that targets the CD3 receptor. Muromonab blocks all cytotoxic T cell functions. Muromonab is also used as an immunosuppressant to reduce acute solid organ transplant rejection. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Mouse IgG2a |
| Light Chain Type | kappa |
| SDS-PAGE | 146.34 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 140608-64-6 |
Muromonab (anti-CD3) (Ab170491) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD3 with Muromonab (anti-CD3) (Ab170491) (right panel) conjugated with biotin compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Muromonab (anti-CD3) (Ab170491) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD3 (red) with Muromonab (anti-CD3) (Ab170491) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Muromonab (anti-CD3) (Ab170491) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling CD3 (red) with Muromonab (anti-CD3) (Ab170491). Goat Anti-Human IgG (FITC) (Ab175834) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Muromonab (anti-CD3) (Ab170491) - SEC
The purity of Muromonab (anti-CD3) (Ab170491) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0708072 | Certificate of Analysis | Jul 10, 2024 | Ab170491 |
| ZJ23F1001371 | Certificate of Analysis | Oct 18, 2023 | Ab170491 |
| ZJ23F1001372 | Certificate of Analysis | Oct 18, 2023 | Ab170491 |
| 1. Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions.. MAbs, 2 (2): (129-36). [PMID:20190561] |
| 2. Soudais C, de Villartay JP, Le Deist F, Fischer A, Lisowska-Grospierre B. (1993) Independent mutations of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency.. Nat Genet, 3 (1): (77-81). [PMID:8490660] |
| 3. de Saint Basile G, Geissmann F, Flori E, Uring-Lambert B, Soudais C, Cavazzana-Calvo M, Durandy A, Jabado N, Fischer A, Le Deist F. (2004) Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3.. J Clin Invest, 114 (10): (1512-7). [PMID:15546002] |
| 4. Mathur D, Root AR, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, Kearney JC, Lucas J, Guffroy M, Golas J et al.. (2020) A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.. Clin Cancer Res, 26 (9): (2188-2202). [PMID:31996389] |
| 5. Borroto A, Reyes-Garau D, Jiménez MA, Carrasco E, Moreno B, Martínez-Pasamar S, Cortés JR, Perona A, Abia D, Blanco S et al.. (2016) First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.. Sci Transl Med, 8 (370): (370ra184). [PMID:28003549] |
| 6. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.. Sci Transl Med, 7 (287): (287ra70). [PMID:25972002] |
| 7. Lanier, L L LL, Chang, C C, Spits, H H and Phillips, J H JH.. (1992) Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:1387664] |
| 8. Barber, E K EK, Dasgupta, J D JD, Schlossman, S F SF, Trevillyan, J M JM and Rudd, C E CE.. (1989) The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2470098] |
| 9. Gold, D P DP and 6 more authors.. (1986) Isolation of cDNA clones encoding the 20K non-glycosylated polypeptide chain of the human T-cell receptor/T3 complex.. Nature, [PMID:3012357] |
| 10. Salomon, Arthur R AR and 10 more authors.. (2003) Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.. Proceedings of the National Academy of Sciences of the United States of America, (21): [PMID:12522270] |
| 11. Brill, Laurence M LM and 5 more authors.. (2004) Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.. Analytical chemistry, (15): [PMID:15144186] |
| 12. Gimferrer, Idoia I and 8 more authors.. (2004) Relevance of CD6-mediated interactions in T cell activation and proliferation.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:15294938] |
| 13. Arnett, Kelly L KL, Harrison, Stephen C SC and Wiley, Don C DC.. (2004) Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment.. Proceedings of the National Academy of Sciences of the United States of America, (16): [PMID:15534202] |
| 14. Gaglia, Jason and Kissler, Stephan.. (2019) Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.. Biochemistry, (8): [PMID:31523950] |
| 15. Clevers, H C HC, Dunlap, S S, Wileman, T E TE and Terhorst, C C.. (1988) Human CD3-epsilon gene contains three miniexons and is transcribed from a non-TATA promoter.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:3267235] |
| 16. Fütterer, K K, Wong, J J, Grucza, R A RA, Chan, A C AC and Waksman, G G.. (1998) Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide.. Journal of molecular biology, (21): [PMID:9698567] |
| 17. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352] |
